NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Down 31.8% in January

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the recipient of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 161,300 shares, a drop of 31.8% from the January 15th total of 236,500 shares. Currently, 1.1% of the company’s stock are short sold. Based on an average daily trading volume, of 271,300 shares, the short-interest ratio is currently 0.6 days.

NeuroSense Therapeutics Trading Down 1.3 %

Shares of NRSN traded down $0.02 during mid-day trading on Friday, hitting $1.16. The company’s stock had a trading volume of 68,477 shares, compared to its average volume of 164,606. The firm has a market capitalization of $15.79 million, a price-to-earnings ratio of -1.80 and a beta of 1.27. The company’s 50-day moving average is $1.13 and its 200-day moving average is $1.09. NeuroSense Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.33.

NeuroSense Therapeutics (NASDAQ:NRSN) last posted its earnings results on Wednesday, December 18th. The company reported ($0.11) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reaffirmed a “hold” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 16th.

Institutional Investors Weigh In On NeuroSense Therapeutics

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Jane Street Group LLC purchased a new stake in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 64,636 shares of the company’s stock, valued at approximately $78,000. Jane Street Group LLC owned approximately 0.47% of NeuroSense Therapeutics as of its most recent filing with the SEC. 1.04% of the stock is owned by hedge funds and other institutional investors.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.